Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma

摘要: BACKGROUND Mutations of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) are identified in almost half all papillary thyroid carcinomas (PTCs). These mutations specific for PTC and may confer a worse prognosis. An immunohistochemical (IHC) stain BRAF is commercially available has been validated surgical specimens. Fine-needle aspiration (FNA) frequently used as diagnostic tool risk stratification nodules. Therefore, the authors evaluated performance immunostaining with anti-BRAF antibody VE1 on FNA direct smears. METHODS The 51 specimens that had subsequent resection diagnosis PTC. IHC was performed to determine their mutation status. The corresponding smears were then stained using same assess correlation. RESULTS Twenty-two 46 included positive (47.8%) by IHC, consistent published rates. paired cytologic from these cases revealed 65.3% concordance. overall sensitivity staining 63.6%, specificity 58.3%. Concordance rates highest diagnosed malignant or suspicious malignancy (75% 85.7%, respectively). negative predictive value increased 77.8% when follicular neoplasm/suspicious combined. CONCLUSIONS Specimens most likely be concordant. Limitations interpretation low cellularity obscuring blood, macrophages, colloid. With further refinement, it possible immunocytochemistry can applied prospectively FNAs reduce false-negative Cancer (Cancer Cytopathol) 2015;123:531–539. © 2015 American Society.